FATENT COOPERATION TREATY

RECEIVED

MAR 0 1 2005

RANBAXY
I.P DEPARTMENT

From the INTERNATIONAL SEARCHING AUTHORITY

To:

RANBAXY LABORATORIES LIMITED Attn. Deshmukh, Jay R. 600 College Road East Suite 2100 Princeton, NJ 08540 NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY. OR THE DECLARATION

"X" refs.

UNITED STATES OF AMERICA	(PCT Rule 44.1)		
	Date of mailing (day/month/year) 23/02/2005		
Applicant's or agent's file reference			
RLL-438WO	FOR FURTHER ACTION See paragraphs 1 and 4 below		
International application No.	International filing date		
PCT/IB2004/002959	(day/month/year) 13/09/2004		
Applicant			
RANBAXY LABORATORIES LIMITED			

	Authority have been established and are transmitted herewith.					
	Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):					
	When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.					
	Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes 1211 Geneva 20, Switzerland, Fascimile No.: (41–22) 740.14.35					
	For more detailed instructions, see the notes on the accompanying sheet.					
2. 🗌	The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.					
3.	With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:					
	the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.					

1. 🗽 The applicant is hereby notified that the international search report and the written opinion of the International Searching

4. Reminders

Shortly after the expiration of **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90*bis*.1 and 90*bis*.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fax: (+31-70) 340-2040, 1x.

Authorized officer

Sandrine Parriche

riche (ENTE

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international pbulication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been its filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added.
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
 "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide

Notes to Form PCT/ISA/220 (second sheet) (January 1994)

FAIENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference RLL-438WO	FOR FURTHER ACTION as we	see Form PCT/ISA/220 ell as, where applicable, item 5 below.			
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)			
PCT/IB2004/002959	13/09/2004	12/09/2003			
Applicant	Applicant				
RANBAXY LABORATORIES LIMI	TED				
This International Search Report has bee according to Article 18. A copy is being tr	en prepared by this International Searching At ansmitted to the International Bureau.	uthority and is transmitted to the applicant			
l —	s of a total of sheets. y a copy of each prior art document cited in the	is report.			
	1. Basis of the report a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.				
this Authority (Ru	ule 23.1(b)).	slation of the international application furnished to			
b. With regard to any nucle	otide and/or amino acid sequence disclose	ed in the international application, see Box No. I.			
2. Certain claims were fo	und unsearchable (See Box II).				
3. Unity of invention is la	cking (see Box III).				
4. With regard to the title,					
	ubmitted by the applicant.				
the text has been establi	shed by this Authority to read as follows:				
5. With regard to the abstract,					
i —	ubmitted by the applicant.				
the text has been establi may, within one month fr	shed, according to Rule 38.2(b), by this Authon the date of mailing of this international se	ority as it appears in Box No. IV. The applicant arch report, submit comments to this Authority.			
6. With regard to the drawings,					
a. the figure of the drawings to be	published with the abstract is Figure No.				
as suggested by	• •	wasset a figure			
	nis Authority, because the applicant failed to so his Authority, because this figure better chara				
	be published with the abstract.				

INTERI TIONAL SEARCH REPORT

int onal Application No PCT/IB2004/002959

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C51/363 C07C51/347 C07C65/21 C07C67/00 C07C69/84 A61P11/06 C07C69/92 A61K31/44 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P CO7C Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. P,X WO 2004/033430 A (ALBEMARLE CORPORATION) 46,47, 22 April 2004 (2004-04-22) 50,51 page 1, line 6 - line 12; example 3 page 6, line 15 - line 22 Χ REID P: "ROFLUMILAST" 46,47 CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 3, no. 8, August 2002 (2002-08), pages 1165-1170, XP001119630 ISSN: 0967-8298 the whole document Α US 5 712 298 A (AMSCHLER ET AL) 1-51 27 January 1998 (1998-01-27) cited in the application column 9 - column 11 Further documents are listed in the continuation of box C. X Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not cited to understand the principle or theory underlying the considered to be of particular relevance invention "E" earlier document but published on or after the international *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to "L" document which may throw doubts on priority claim(s) or involve an inventive step when the document is taken alone which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-O document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means *P* document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 15 February 2005 23/02/2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Österle, C

.-rnational application No. PCT/IB2004/002959

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 47 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest
No protest accompanied the payment of additional search fees.

INTER' TIONAL SEARCH REPORT

Information on patent family members

Int ional Application No PCT/IB2004/002959

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 2004033430	Α	22-04-2004	US	6822114 B1	23-11-2004
			WO	2004033430 A2	22-04-2004
US 5712298	Α	27-01-1998	AT	217612 T	15-06-2002
			ΑU	687087 B2	19-02-1998
			ΑU	7490794 A	24-01-1995
			CA	2165192 A1	12-01-1995
			CN	1126468 A ,C	10-07-1996
			CY	2389 A	10-09-2004
			CZ	9600001 A3	12-06-1996
			DE	59410119 D1	20-06-2002
			DK	706513 T3	09-09-2002
			WO	9501338 A1	12-01-1995
			EP	0706513 A1	17-04-1996
			ES	2176252 T3	01-12-2002
			FI	956333 A	29-12-1995
			HK	1011690 A1	11-10-2002
			HU	73232 A2	29-07-1996
			JP	8512041 T	17-12-1996
			JP	3093271 B2	03-10-2000
			NO	955211 A	21-12-1995
			NZ	271316 A	24-11-1997
			PL	311820 A1	18-03-1996
			PT	706513 T	31-10-2002
			RU	2137754 C1	20-09-1999
			SI	706513 T1	31-10-2002
			SK	161795 A3	03-07-1996

I... TENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

see form PCT/ISA/220

To:

MAR 0, 2005

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date	of m	ailina	

(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference see form PCT/ISA/220

FOR FURTHER ACTION

See paragraph 2 below

International application No. PCT/IB2004/002959

International filing date (day/month/year)

12.09.2003

13.09.2004

Priority date (day/month/year)

International Patent Classification (IPC) or both national classification and IPC

C07C51/363, C07C51/347, C07C65/21, C07C67/00, C07C69/84, C07C69/92, A61K31/44, A61P11/06

RANBAXY LABORATORIES LIMITED

1. This opinion contains indications relating to the following items:

Box No. I Basis of the opinion

Box No. II **Priority**

Box No. III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

☐ Box No. IV Lack of unity of invention

Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial

applicability; citations and explanations supporting such statement

☑ Box No. VI Certain documents cited

Box No. VII Certain defects in the international application

Box No. VIII Certain observations on the international application

2. **FURTHER ACTION**

Box No. V

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d

Fax: +49 89 2399 - 4465

Authorized Officer

Österle, C

Telephone No. +49 89 2399-8120





20/571401

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/IB2004/002959

_	Box N	o. I Basis of the opinion			
1.	With regard to the language , this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.				
	la	nis opinion has been established on the basis of a translation from the original language into the following nguage , which is the language of a translation furnished for the purposes of international search nder Rules 12.3 and 23.1(b)).			
2.	With reneces:	egard to any nucleotide and/or amino acid sequence disclosed in the international application and sary to the claimed invention, this opinion has been established on the basis of:			
	a. type	of material:			
		a sequence listing			
		table(s) related to the sequence listing			
	b. form	nat of material:			
		in written format			
		in computer readable form			
	c. time	of filing/furnishing:			
		contained in the international application as filed.			
		filed together with the international application in computer readable form.			
		furnished subsequently to this Authority for the purposes of search.			
3.	ha co	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto is been filed or furnished, the required statements that the information in the subsequent or additional spies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.			
4.	Additio	nal comments:			

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2004/002959

	Box No.	Il Priority			
1.	□ The	llowing document has not been furnished:			
		copy of the earlier application whose priority has been claimed (Rule 43 <i>bis</i> .1 and 66.7(a)).			
		translation of the earlier application whose priority has been claimed (Rule 43 <i>bis</i> .1 and 66.7(b)).			
		sequently it has not been possible to consider the validity of the priority claim. This opinion has ertheless been established on the assumption that the relevant date is the claimed priority date.			
2. [has	opinion has been established as if no priority had been claimed due to the fact that the priority claim been found invalid (Rules 43 <i>bis</i> .1 and 64.1). Thus for the purposes of this opinion, the international date indicated above is considered to be the relevant date.			
3. [was	is not been possible to consider the validity of the priority claim because a copy of the priority document not available to the ISA at the time that the search was conducted (Rule 17.1). This opinion has ertheless been established on the assumption that the relevant date is the claimed priority date.			
4.	Additiona	al observations, if necessary:			

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2004/002959

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:				
	the entire international application,			
\boxtimes	claims Nos. 47			
bed	cause:			
	the said international application, or the said claims Nos. 47 (method of treatment) relate to the following subject matter which does not require an international preliminary examination (specify):			
	see separate sheet			
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):			
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.			
	no international search report has been established for the whole application or for said claims Nos.			
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:			
	the written form		has not been furnished	
			does not comply with the standard	
	the computer readable form		has not been furnished	
			does not comply with the standard	
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.			
	See separate sheet for further	detai	ds	

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2004/002959

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-45,48-51

No:

Claims

46,47

Inventive step (IS)

Yes: Claims

1-45,48-51

No: Claims

Industrial applicability (IA)

Yes: Claims

s 1-46,48-51

No: Claims

2. Citations and explanations

see separate sheet

Box No. VI Certain documents cited

 Certain published documents (Rules 43bis.1 and 70.10) and /or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/IB2004/002959

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 47 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(I) PCT).

Re Item IV

Lack of unity of invention

Claims 1-26 and 43-45 are directed towards the synthesis of the benzoic acids derivatives of formula I from the compounds of formula II. Claims 27-42 are directed towards the synthesis of the compounds of formula II. Claims 48 and 49 claim a compound of formula II. Claims 50 and 51 claim a compound of formula III, an intermediate in the synthesis of the compounds of formula I.

Claims 46 and 47 relate to a pharmaceutical composition comprising roflumilast and a method of treatment comprising administering roflumilast.

The technical element common to claims 1-45 and 48-51 is the synthesis of the compound of formula I.

Claims 46 and 47 refer to this synthesis by claiming that the roflumilast is obtained by the process of claim 43, e.g. using the process of claim 1. The process by which a certain compound has been made is however not seen as limiting the scope of a claim. The common technical element of claims 46 and 47 then is roflumilast.

Claims 1-45 and 48-51 on the one hand and claims 46 and 47 on the other hand then do not have a common technical element linking the two sets of claims.

In conclusion, the groups of claims are not linked by common or corresponding special technical features and define 2 different inventions not linked by a single general inventive concept.

The application, hence does not meet the requirements of unity of invention as defined in Rules 13.1 and 13.2 PCT.

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- D1: WO 2004/033430 A (ALBEMARLE CORPORATION) 22 April 2004 (2004-04-22)
- D2: REID P: "ROFLUMILAST" CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 3, no. 8, August 2002 (2002-08), pages 1165-1170, XP001119630 ISSN: 0967-8298
- D3: US-A-5 712 298 (AMSCHLER ET AL) 27 January 1998 (1998-01-27)

1. Novelty (Article 33(2) PCT):

1.1 D2 discloses roflumilast, methods of treating for example asthma with roflumilast and pharmaceutical compositions comprising roflumilast (see for example p. 1165 and following pages, "synthesis and SAR" as well as "pharmacology").

The subject-matter of claims 46 and 47 therefore is not novel.

- 1.2 D3, considered the closest prior art, discloses the synthesis of roflumilast from 3-cyclopropylmethoxy-4-difluoromethoxy benzoic acid (according to present claim 1 described as "compound of formula I").
 In D3, the compound of formula I is synthesized from 3-cyclopropylmethoxy-4-difluoromethoxy benzaldehyde.
- 1.3 Present claim 1 claims a process of synthesizing a compound of formula I by reacting 3-cyclopropylmethoxy-4-hydroxy benzoic acid ester with a difluoromethylating agent, followed by a deesterification of the product.

The synthesis of the compound of formula I as claimed in claim 1 then is novel over D3.

Claims 2-26 and 43-45 are also considered novel, since they are dependent on claim 1.

- 1.4 Claim 27 claims a process for preparing a compound of formula II, which is the staring material of the process claimed in claim 1. A compound of formula II is not disclosed in the available prior art and therefore is considered novel. Since the synthesis of a novel compound is also considered novel, the subject-matter of claims 27-42 is considered novel.
- 1.5 In claim 48 the compound of formula II is claimed. As already stated under 1.4 the compounds of formula II are novel.The subject-matter of claims 48 and 49 then are considered novel.
- 1.6 Compounds of formula III of claim 50 are not disclosed in the prior art. The subject-matter of claims 50 and 51 then can be considered novel.

2. Inventive Step (Article 33(3) PCT):

2.1 In D2 the compounds of formula I are synthesized via a different synthetic route then the one claimed in present claim 1.

The technical problem then can be seen in providing an alternative process for synthesizing compounds of formula I.

The problem is solved by the process of claim 1.

The starting material of the process of claim 1 as well as the synthetic route claimed are both novel and aren't suggested anywhere in the prior art.

The subject-matter of claims 1-26 and 43-45 then can be considered inventive.

2.2 The compounds of formula II are new starting materials in the process for synthesizing the compounds of formula I. These compounds then can be also considered inventive.

The subject-matter of claims 48 and 49, as well as of claims 27-42, wherein the synthesis of these novel and inventive compounds is claimed, then can be considered inventive.

- 2.3 The compounds of formula III are intermediates in the process of claim 1 and are considered to structurally contribute to the structure of the compounds of formula I. The subject-matter of claims 50 and 52 then also can be considered inventive.
- 3. Industrial Applicability (Article 33(4) PCT):
- 3.1 The subject-matter of claims 1-46 and 48-51 is industrially applicable.

Re Item VI

Certain documents cited

Certain published documents

Application No Patent No

Publication date (day/month/year)

Filing date (day/month/year)

Priority date (valid claim) (day/month/year)

WO2004/033430

22/04/2002

06/10/2003

08/10/2002

Re Item VII

Certain defects in the international application

1. The US patent No 6,712,274 seems to be incorrect.